Acadia Pharmaceuticals has made its DAYBUE® STIX powder formulation broadly available in the United States for the treatment of Rett syndrome in patients two years of age and older. The powder is dye‑ and preservative‑free and is bioequivalent to the original oral solution, ensuring the same efficacy and safety profile.
The FDA approved the powder formulation on December 12 2025. Limited availability began in the first quarter of 2026, and the product has been broadly available since early second quarter 2026.
The launch expands Acadia’s commercial reach. The powder offers a more flexible, patient‑centered delivery option that can improve adherence and broaden market penetration across the Rett syndrome patient population.
Acadia’s original oral solution was approved in 2023, making DAYBUE® the first and only FDA‑approved treatment for Rett syndrome in the United States. The new formulation addresses patient and caregiver needs for flexibility, portability, and taste customization.
"Initial feedback from a small group of caregivers following the limited launch revealed that more than 80% of early users reported satisfaction with DAYBUE STIX, highlighting the added flexibility and portability of this new formulation," said Tom Garner, Chief Commercial Officer.
"We are hearing that the new formulation may allow for more customized care in real‑world settings. Ongoing evaluation from patients and caregivers remains a priority as we identify ways to better assist families managing this complex condition," Garner added.
The Rett syndrome treatment market is projected to grow significantly, with estimates ranging from $419.4 million by 2034 (CAGR 7.85%) to $1.5 billion in 2026, expanding to $3.2 billion by 2032 at a 13.5% CAGR. The new powder formulation positions Acadia to capture a larger share of this expanding market.
By offering an alternative dosing format, Acadia strengthens its competitive position and enhances its ability to meet the evolving needs of patients and caregivers, reinforcing its strategy to provide innovative treatments for underserved neurological and rare disease communities.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.